Cyclomics
AI-powered diagnostic solutions
Earlier detection
Better outcomes
About us
At Cyclomics, our story begins with a clear mission: to revolutionize cancer diagnostics through innovation in molecular biology and sequencing.
Founded in the Netherlands, we are a biotechnology company specializing in advanced molecular diagnostics and DNA sequencing technologies.​​
Solutions
Our team of scientists and engineers has developed groundbreaking solutions such as CySeq®, our flagship consensus sequencing and liquid biopsy platform, and Epinn®, an AI-driven framework for rapid tumor classification. Together, these technologies empower clinicians and researchers to detect cancer earlier, monitor disease progression, and guide treatment decisions with greater precision and speed.​
Epinn®
Rapid tumour classification to assist the pathologist during diagnosis. Epinn® combines methylation sequencing with machine learning to classify tumour types quickly and accurately, shortening the timeline from 1 week to <90 minutes.
Epinn is an RUO product
CySeq®
CySeq® is a cutting-edge liquid biopsy and consensus sequencing platform, which enables highly sensitive detection of genetic mutations and cancer biomarkers from blood samples. And enables most comprehensive fragmentomics analysis on the market.
CySeq is an RUO product